Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies
Recruiting
Observational Study
Leukemia, Acute
MDS
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 60 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 20 (estimated)
- Sponsor
- Abramson Cancer Center at Penn Medicine · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The purpose of this research study is to determine if frailty assessments can be used to predict how well patients aged 60 years and older will do after chemotherapy, CAR T-cell therapy, or allogeneic stem cell transplant.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Eligibility Criteria Arm A:
* Age 60 years or older.
* New diagnosis of Acute Leukemia or MDS, or suspected diagnosis.
* Able to consent to the study.
Eligibility Criteria Arm B:
* Age 60 years or older with a hematologic malignancy.
* Plan to undergo an allogeneic blood or marrow transplantation…
Contacts